Cas9 Stable Cell Line - BJ

The Cas9 stable cell line-BJ is a genetically engineered human fibroblast cell line derived from the primary BJ cell line, which originates from normal neonatal foreskin tissue. This cell line has been modified to stably express the Streptococcus pyogenes Cas9 nuclease, a key component of the CRISPR-Cas9 genome editing system. Through lentiviral transduction and antibiotic selection, these cells maintain stable Cas9 expression during passage, ensuring reliable gene editing without the need for repeated transfections. The BJ parental cell line exhibits typical fibroblast morphology, adherent growth characteristics, and a diploid karyotype, making it ideal for studying human cellular processes in non-cancer environments.

The Cas9 stable cell line-BJ holds broad application potential in biomedical research, particularly in functional genomics and therapeutic drug development. Researchers utilize this cell line for highly efficient gene knockout studies, where guide RNA (gRNA) targets specific genes to investigate loss-of-function phenotypes in areas such as DNA repair, aging, or metabolic pathways. This cell line is compatible with array-based or hybrid CRISPR screening and can be used to identify genes involved in disease mechanisms, such as cancer progression or neurodegenerative diseases, across the entire genome. Furthermore, this cell line facilitates precise gene knock-in experiments, inserting reporter tags, disease-related mutations, or therapeutic transgenes via homologous recombination repair (HDR). In drug discovery, this cell line can serve as a tool for validating drug targets by constructing homologous cell models with engineered mutations and evaluating the efficacy of compounds.